FDA approves first treatment for chronic hepatitis delta virus infection

MedicalXpress | 六月 05, 2026

The U.S. Food and Drug Administration has approved Hepcludex (bulevirtide‐gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or compensated cirrhosis. Approval of Hepcludex was granted to Gilead Sciences.